Tatsuo Kanda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3187391/publications.pdf

Version: 2024-02-01

253 papers

5,807 citations

36 h-index 62 g-index

257 all docs

257 docs citations

times ranked

257

6854 citing authors

#	Article	IF	CITATIONS
1	Left Gastric Vein Width Is an Important Risk Factor for Exacerbation of Esophageal Varices Post Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices in Cirrhotic Patients. Medicina (Lithuania), 2022, 58, 205.	0.8	7
2	Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes. International Journal of Molecular Sciences, 2022, 23, 2631.	1.8	12
3	A Case of Recent Liver Injury Induced by Benzbromarone. Reports, 2022, 5, 8.	0.2	O
4	Contrast-enhanced ultrasonography for blood flow detection in hepatocellular carcinoma during lenvatinib therapy. Journal of Medical Ultrasonics (2001), 2022, 49, 425-432.	0.6	2
5	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 48-60.	4.2	25
6	Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. Cancers, 2022, 14, 2549.	1.7	10
7	Evaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking. International Journal of Molecular Sciences, 2022, 23, 6044.	1.8	6
8	Hepatitis A Virus Infection and Molecular Research. International Journal of Molecular Sciences, 2022, 23, 7214.	1.8	2
9	The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus Replication and Growth of Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences, 2022, 23, 7878.	1.8	4
10	Quantitative Ultrasound Image Analysis Helps in the Differentiation of Hepatocellular Carcinoma () Tj ETQq0 0 0 Invasion. Journal of Ultrasound in Medicine, 2021, 40, 689-698.	rgBT /Ove 0.8	erlock 10 Tf 50 4
11	A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment. Acta Hepatologica Japonica, 2021, 62, 25-32.	0.0	1
12	Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. Journal of Cancer, 2021, 12, 2694-2701.	1.2	8
13	Male-Dominant Hepatitis A Outbreak Observed among Non-HIV-Infected Persons in the Northern Part of Tokyo, Japan. Viruses, 2021, 13, 207.	1.5	5
14	Artificial intelligence and machine learning could support drug development for hepatitis A virus internal ribosomal entry sites. Artificial Intelligence in Gastroenterology, 2021, 2, 1-9.	0.2	0
15	Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines. Scientific Reports, 2021, 11, 3703.	1.6	5
16	HCV GT1b-patient with alanine aminotransferase elevation and sustained virologic response achieved by grazoprevir/elbasvir discontinuation. Future Virology, 2021, 16, 161-165.	0.9	1
17	The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Scientific Reports, 2021, 11, 5303.	1.6	20
18	Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2021, 549, 171-178.	1.0	13

#	Article	IF	CITATIONS
19	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 473-484.	4.2	28
20	No additive effects of peginterferon on the short-term improvement of liver histology by entecavir monotherapy in chronic hepatitis B patients. Hepatology International, 2021, 15, 579-581.	1.9	0
21	Large-volume cell-free and concentrated ascites reinfusion therapy improves venous flow in patients with liver cirrhosis. Journal of Medical Ultrasonics (2001), 2021, 48, 315-322.	0.6	O
22	Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer. JGH Open, 2021, 5, 722-724.	0.7	2
23	Ultrasonographic grayscale findings related to fibrosis in patients with non-alcoholic fatty liver disease: comparison with transient elastography and Fib-4 index. Journal of Medical Ultrasonics (2001), 2021, 48, 323-333.	0.6	2
24	Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication. International Journal of Molecular Sciences, 2021, 22, 7420.	1.8	8
25	Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients. Medicina (Lithuania), 2021, 57, 761.	0.8	5
26	Magnetic resonance elastography-based prediction of hepatocellular carcinoma recurrence after curative resection. Surgery, 2021, 170, 167-172.	1.0	8
27	A case of Takotsubo cardiomyopathy after microwave ablation therapy for hepatocellular carcinoma. Acta Hepatologica Japonica, 2021, 62, 548-554.	0.0	0
28	Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir. Internal Medicine, 2021, 60, 2061-2066.	0.3	1
29	Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 38-51.	4.2	58
30	Laparoscopic bypass surgery as palliative treatment for duodenal obstruction due to lymph node metastasis invasion of hepatocellular carcinoma. Acta Hepatologica Japonica, 2021, 62, 656-662.	0.0	0
31	EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Scientific Reports, 2021, 11, 21396.	1.6	17
32	The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection. Viruses, 2021, 13, 2216.	1.5	1
33	Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells. Cell Death and Disease, 2021, 12, 1073.	2.7	9
34	Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series. Anticancer Research, 2021, 41, 6225-6230.	0.5	5
35	Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan. Journal of Clinical Medicine, 2021, 10, 5529.	1.0	4
36	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Investigational New Drugs, 2020, 38, 172-180.	1.2	57

#	Article	IF	CITATIONS
37	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer, 2020, 9, 596-612.	4.2	10
38	Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. Journal of Gastroenterology, 2020, 55, 977-989.	2.3	8
39	Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives. International Journal of Molecular Sciences, 2020, 21, 4906.	1.8	19
40	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 382-396.	4.2	54
41	Involvement of the Interferon Signaling Pathways in Pancreatic Cancer Cells. Anticancer Research, 2020, 40, 4445-4455.	0.5	13
42	Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease. International Journal of Molecular Sciences, 2020, 21, 6384.	1.8	9
43	Analysis of full-length hepatitis B virus genome from chronic hepatitis B-patients with higher alanine aminotransferase elevation. Future Virology, 2020, 15, 429-439.	0.9	0
44	Additive Effects of Zinc Chloride on the Suppression of Hepatitis A Virus Replication by Interferon in Human Hepatoma Huh7 Cells. In Vivo, 2020, 34, 3301-3308.	0.6	12
45	Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines. International Journal of Molecular Sciences, 2020, 21, 3349.	1.8	20
46	Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection. Viruses, 2020, 12, 533.	1.5	18
47	Analysis of HBV Genomes Integrated into the Genomes of Human Hepatoma PLC/PRF/5 Cells by HBV Sequence Capture-Based Next-Generation Sequencing. Genes, 2020, 11, 661.	1.0	19
48	Long-term administration of Tolvaptan to patients with decompensated cirrhosis. International Journal of Medical Sciences, 2020, 17, 874-880.	1.1	5
49	Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 1525.	1.8	66
50	Application of artificial intelligence in hepatology: Minireview. Artificial Intelligence in Gastroenterology, 2020, 1, 5-11.	0.2	8
51	High platelet count as a poor prognostic factor for liver cancer patients without cirrhosis. BioScience Trends, 2020, 14, 368-375.	1.1	7
52	Association of Genetic Polymorphisms With Hepatitis C Virus-related Liver Cirrhosis in Japan. In Vivo, 2020, 34, 3309-3313.	0.6	0
53	Prognostic four-gene signature for overall survival in patients with hepatocellular carcinoma. Hepatology International, 2019, 13, 519-520.	1.9	2
54	Antiviral activity of zinc sulfate against hepatitis A virus replication. Future Virology, 2019, 14, 399-406.	0.9	12

#	Article	IF	CITATIONS
55	Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease. International Journal of Medical Sciences, 2019, 16, 909-921.	1.1	7
56	Follow-up Results of HCV GT2 Patients After Sofosbuvir/Ribavirin Therapy: Careful Attention to Occurrence of HCC. Anticancer Research, 2019, 39, 3855-3862.	0.5	5
57	Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virus. International Journal of Medical Sciences, 2019, 16, 1366-1370.	1.1	9
58	Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer, 2019, 19, 1088.	1.1	28
59	Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma. BMC Gastroenterology, 2019, 19, 147.	0.8	5
60	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatology International, 2019, 13, 649-661.	1.9	72
61	Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?. Hepatobiliary Surgery and Nutrition, 2019, 8, 423-425.	0.7	0
62	POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33. Scientific Reports, 2019, 9, 102.	1.6	23
63	Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. International Journal of Molecular Sciences, 2019, 20, 1358.	1.8	184
64	Exosomes and Hepatocellular Carcinoma: From Bench to Bedside. International Journal of Molecular Sciences, 2019, 20, 1406.	1.8	91
65	Long-term follow-up of a Japanese patient with hepatitis B virus genotype H and human immunodeficiency virus coinfection. Future Virology, 2019, 14, 633-639.	0.9	2
66	Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients. Journal of Medical Virology, 2019, 91, 411-418.	2.5	19
67	Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. Journal of Gastroenterology, 2019, 54, 87-95.	2.3	83
68	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?. Hepatology International, 2019, 13, 103-109.	1.9	26
69	Nutritional Treatment of Liver Disease. Journal of the Nihon University Medical Association, 2019, 78, 231-236.	0.0	0
70	Successful Management of a Patient with Multiple Nucleos(t)ide Analogue-Resistant Hepatitis B Virus and Diffuse Large B Cell Lymphoma Using Tenofovir Disoproxil Fumarate: A Case Report. Journal of the Nihon University Medical Association, 2019, 78, 295-300.	0.0	0
71	Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response. Hepatology International, 2018, 12, 90-93.	1.9	9
72	Key HLAâ€DRB1â€DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. Hepatology, 2018, 68, 848-858.	3.6	53

#	Article	IF	Citations
73	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. Journal of Gastroenterology, 2018, 53, 247-257.	2.3	15
74	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Investigational New Drugs, 2018, 36, 332-339.	1.2	52
75	Apoptosis and non-alcoholic fatty liver diseases. World Journal of Gastroenterology, 2018, 24, 2661-2672.	1.4	189
76	Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. Hepatology International, 2018, 12, 523-530.	1.9	24
77	Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection. International Journal of Medical Sciences, 2018, 15, 466-474.	1.1	20
78	Early Combination Therapy with Corticosteroid and Nucleoside Analogue Induces Rapid Resolution of Inflammation in Acute Liver Failure due to Transient Hepatitis B Virus Infection. Internal Medicine, 2018, 57, 1543-1552.	0.3	11
79	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. Scientific Reports, 2018, 8, 7958.	1.6	38
80	Hepatitis B Virus Genotype C is Predominant in Myanmar. Diseases (Basel, Switzerland), 2018, 6, 3.	1.0	2
81	Determination of serum carbohydrate-deficient transferrin by a nephelometric immunoassay for differential diagnosis of alcoholic and non-alcoholic liver diseases. Clinica Chimica Acta, 2018, 485, 181-186.	0.5	6
82	Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt. Hepatology International, 2018, 12, 291-293.	1.9	6
83	Inhibitory effect of Japanese rice-koji miso extracts on hepatitis A virus replication in association with the elevation of glucose-regulated protein 78 expression. International Journal of Medical Sciences, 2018, 15, 1153-1159.	1.1	19
84	Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. Oncotarget, 2018, 9, 5509-5513.	0.8	5
85	Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget, 2018, 9, 11631-11637.	0.8	10
86	Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. Oncotarget, 2018, 9, 16263-16270.	0.8	5
87	Association of mRNA expression of iron metabolism-associated genes and progression of non-alcoholic steatohepatitis in rats. Oncotarget, 2018, 9, 26183-26194.	0.8	10
88	Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. World Journal of Hepatology, 2018, 10, 898-906.	0.8	7
89	Interferon-Free Treatment for Chronic Hepatitis C in Japan. Journal of the Nihon University Medical Association, 2018, 77, 123-125.	0.0	0
90	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. Oncotarget, 2018, 9, 21560-21568.	0.8	6

#	Article	IF	CITATIONS
91	The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. Journal of Gastroenterology, 2017, 52, 113-122.	2.3	10
92	Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatology International, 2017, 11, 38-44.	1.9	16
93	Genome-wide association studies identifyPRKCBas a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. Human Molecular Genetics, 2017, 26, ddw406.	1.4	46
94	Glucose-regulated protein 78 is an antiviral against hepatitis A virus replication. Experimental and Therapeutic Medicine, 2017, 13, 3305-3308.	0.8	20
95	Overexpression of the androgen receptor in human hepatoma cells and its effect on fatty acid metabolism. Oncology Letters, 2017, 13, 4481-4486.	0.8	8
96	Interferon induces interleukin 8 and bone marrow stromal cell antigen 2 expression, inhibiting the production of hepatitis B virus surface antigen from human hepatocytes. Biochemical and Biophysical Research Communications, 2017, 486, 858-863.	1.0	9
97	Free fatty acids or high-concentration glucose enhances hepatitis A virus replication in association with a reduction in glucose-regulated protein 78 expression. Biochemical and Biophysical Research Communications, 2017, 483, 694-699.	1.0	12
98	Hepatitis A virus genotype IA-infected patient with marked elevation of aspartate aminotransferase levels. Clinical Journal of Gastroenterology, 2017, 10, 52-56.	0.4	5
99	A case of arteriovenous fistula due to a ruptured hepatic aneurysm during sorafenib therapy for hepatocellular carcinoma. Acta Hepatologica Japonica, 2017, 58, 605-610.	0.0	1
100	Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology, 2017, 6, 30.	1.3	11
101	Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma. Cancers, 2017, 9, 43.	1.7	18
102	Discrepancy between Hepatitis C Virus Genotypes and NS4-Based Serotypes: Association with Their Subgenomic Sequences. International Journal of Molecular Sciences, 2017, 18, 172.	1.8	1
103	Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. International Journal of Molecular Sciences, 2017, 18, 906.	1.8	28
104	Suspected heparin-induced thrombocytopenia in patients with advanced hepatocellular carcinoma following hepatic arterial infusion chemotherapy. Acta Hepatologica Japonica, 2017, 58, 647-653.	0.0	2
105	Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis. PLoS ONE, 2017, 12, e0177302.	1.1	28
106	Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy. International Journal of Medical Sciences, 2017, 14, 1088-1093.	1.1	0
107	Drug-Induced Liver Injury Associated with Complementary and Alternative Medicines. Case Reports in Gastroenterology, 2017, 10, 706-713.	0.3	0
108	Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. PLoS ONE, 2017, 12, e0174153.	1.1	38

#	Article	IF	Citations
109	Direct-acting antiviral agents against hepatitis C virus and lipid metabolism. World Journal of Gastroenterology, 2017, 23, 5645.	1.4	10
110	Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World Journal of Gastroenterology, 2017, 23, 8120-8127.	1.4	6
111	Pneumocystis jirovecii pneumonia Suspected Due to Low-Dosage Prednisolone Treatment for Acute Autoimmune Hepatitis: Case Report and Literature Review. , 2017, 1, .		0
112	Response-Guided Treatment with an Ultrarapid Virological Response Creates the Future of Interferon-Free Treatment against Hepatitis C. , 2017, 1, .		0
113	Successful Treatment of a Pregnant Woman with Chronic Active Hepatitis B using Tenofovir Disoproxil Fumarate. OBM Hepatology and Gastroenterology, 2017, 01, 1-1.	0.0	1
114	Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. International Journal of Medical Sciences, 2016, 13, 310-315.	1.1	11
115	Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. International Journal of Medical Sciences, 2016, 13, 418-423.	1.1	27
116	Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases. Diseases (Basel, Switzerland), 2016, 4, 38.	1.0	4
117	Successful Management of Acute Liver Failure Patients Waiting for Liver Transplantation by On-Line Hemodiafiltration with an Arteriovenous Fistula. Case Reports in Gastroenterology, 2016, 10, 144-150.	0.3	4
118	Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells. PLoS ONE, 2016, 11, e0146314.	1.1	19
119	Analysis of infectious complications and timing for emergency liver transplantation in autoimmune acute liver failure. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 212-219.	1.4	16
120	Cooperative effects of hepatitis B virus and TNF may play important roles in the activation of metabolic pathways through the activation of NF-κB. International Journal of Molecular Medicine, 2016, 38, 475-481.	1.8	16
121	Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatology International, 2016, 10, 574-593.	1.9	18
122	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatology International, 2016, 10, 681-701.	1.9	75
123	APASL consensus statements and recommendation on treatment of hepatitis C. Hepatology International, 2016, 10, 702-726.	1.9	189
124	Autoimmune hepatitis following drug-induced liver injury in an elderly patient. Clinical Journal of Gastroenterology, 2016, 9, 156-159.	0.4	11
125	Infectious complications, steroid use and timing for emergency liver transplantation in acute liver failure: analysis in a Japanese center. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 756-762.	1.4	13
126	Twoâ€dimensional shear wave elastography with propagationâ€based reliability assessment for grading hepatic fibrosis and portal hypertension. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 595-602.	1.4	21

#	Article	IF	CITATIONS
127	Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation. Case Reports in Gastroenterology, 2016, 10, 248-256.	0.3	5
128	Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Reports in Gastroenterology, 2016, 10, 366-372.	0.3	8
129	Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report. BMC Gastroenterology, 2016, 16, 66.	0.8	7
130	Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. Oncology, 2016, 90, 199-208.	0.9	9
131	Hepatitis C virus genotypes in Myanmar. World Journal of Gastroenterology, 2016, 22, 6095.	1.4	8
132	Sofosbuvir treatment and hepatitis C virus infection. World Journal of Hepatology, 2016, 8, 183.	0.8	15
133	Internal Medicine, 2015, 104, 1861-1865.	0.0	0
134	Recent Trend of Hepatitis E Virus Infection in Chiba Area, Japan: 3 of 5 Cases with Rheumatoid Arthritis. Case Reports in Gastroenterology, 2015, 9, 317-326.	0.3	8
135	Importance of the poor prognosis of severe and fulminant hepatitis in the elderly in an era of a highly aging society: Analysis in a <scp>J</scp> apanese center. Hepatology Research, 2015, 45, 863-871.	1.8	9
136	The androgen receptor as an emerging target in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2015, 2, 91.	1.8	39
137	Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World Journal of Gastroenterology, 2015, 21, 12989.	1.4	58
138	Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy. International Journal of Molecular Sciences, 2015, 16, 21177-21190.	1.8	1
139	Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-ÎB-Nuclear Translocation. PLoS ONE, 2015, 10, e0131973.	1.1	4
140	HBV Core Protein Enhances Cytokine Production. Diseases (Basel, Switzerland), 2015, 3, 213-220.	1.0	10
141	Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype. Case Reports in Gastroenterology, 2015, 9, 215-220.	0.3	4
142	Reappearance of serum hepatitis B viral DNA in patients with hepatitis B surface antigen seroclearance. Hepatology, 2015, 62, 1329-1329.	3.6	9
143	Factors associated with the effect of interferonâ€Î± sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B. Hepatology Research, 2015, 45, 1195-1202.	1.8	22
144	Sustained virologic response achieved after curative treatment of hepatitis ⟨scp⟩C⟨/scp⟩ virusâ€related hepatocellular carcinoma as an independent prognostic factor. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1197-1204.	1.4	36

#	Article	IF	Citations
145	Faldaprevir for the Treatment of Hepatitis C. International Journal of Molecular Sciences, 2015, 16, 4985-4996.	1.8	16
146	Association between hepatitis B virus and MHC class I polypeptide-related chain A in human hepatocytes derived from human-mouse chimeric mouse liver. Biochemical and Biophysical Research Communications, 2015, 464, 1192-1195.	1.0	12
147	The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication inÂHuh7 cells. Biochemical and Biophysical Research Communications, 2015, 458, 908-912.	1.0	30
148	A semi–supervised tensor regression model for siRNA efficacy prediction. BMC Bioinformatics, 2015, 16, 80.	1,2	13
149	Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatology International, 2015, 9, 486-507.	1.9	18
150	HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatology International, 2015, 9, 424-430.	1.9	30
151	The sirtuin inhibitor sirtinol inhibits hepatitis A virus (HAV) replication by inhibiting HAV internal ribosomal entry site activity. Biochemical and Biophysical Research Communications, 2015, 466, 567-571.	1.0	25
152	MicroRNA-122 Inhibits the Production of Inflammatory Cytokines by Targeting the PKR Activator PACT in Human Hepatic Stellate Cells. PLoS ONE, 2015, 10, e0144295.	1.1	37
153	Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus. Journal of Clinical and Translational Hepatology, 2015, 3, 205-210.	0.7	19
154	Current and future directions for treating hepatitis B virus infection. World Journal of Hepatology, 2015, 7, 1541.	0.8	26
155	Current management of patients with hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 1913.	0.8	40
156	Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World Journal of Hepatology, 2015, 7, 1125.	0.8	11
157	Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World Journal of Hepatology, 2015, 7, 1133.	0.8	24
158	Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. World Journal of Virology, 2015, 4, 178.	1.3	4
159	Hepatitis C Virus Nonstructural Protein 5A Inhibits Thapsigargin-Induced Apoptosis. PLoS ONE, 2014, 9, e113499.	1.1	14
160	Ultra-Deep Sequencing Analysis of the Hepatitis A Virus 5 < b > ' < /b > - Untranslated Region among Cases of the Same Outbreak from a Single Source. International Journal of Medical Sciences, 2014, 11, 60-64.	1,1	8
161	Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. International Journal of Medical Sciences, 2014, 11, 707-712.	1.1	21
162	New treatments for genotype 1 chronic hepatitis C & Dinical Risk Management, 2014, 10, 387.	0.9	17

#	Article	IF	Citations
163	18F-fluorodeoxyglucose positron emission tomography might be useful for diagnosis of hepatic amyloidosis. International Medical Case Reports Journal, 2014, 7, 103.	0.3	1
164	Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase cleavage in human pancreatic cancer cells exposed to endoplasmic reticulum stress. Oncology Reports, 2014, 32, 2343-2348.	1.2	13
165	Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment. International Journal of Molecular Sciences, 2014, 15, 21455-21467.	1.8	38
166	IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. International Journal of Hepatology, 2014, 2014, 1-6.	0.4	9
167	Opportunistic infection in patients with acute liver failure. Hepatology International, 2014, 8, 233-239.	1.9	8
168	Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. Experimental Cell Research, 2014, 323, 326-336.	1.2	35
169	Acute Liver Injury in a Patient with Alcohol Dependence: A Case Resembling Autoimmune Hepatitis or Drug-Induced Liver Injury. Case Reports in Gastroenterology, 2014, 8, 129-133.	0.3	3
170	Downregulation of microRNA-431 by human interferon- \hat{l}^2 inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6. International Journal of Oncology, 2014, 44, 1685-1690.	1.4	34
171	Occurrence and Recurrence of Hepatocellular Carcinoma Were Not Rare Events during Phlebotomy in Older Hepatitis C Virus-Infected Patients. Case Reports in Oncology, 2014, 7, 288-296.	0.3	2
172	Suppression of La Antigen Exerts Potential Antiviral Effects against Hepatitis A Virus. PLoS ONE, 2014, 9, e101993.	1.1	21
173	Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection. Journal of Clinical and Translational Hepatology, 2014, 2, 1-6.	0.7	20
174	Hepatitis C virus NS5A inhibitors and drug resistance mutations. World Journal of Gastroenterology, 2014, 20, 2902.	1.4	116
175	Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity. World Journal of Gastroenterology, 2014, 20, 7197.	1.4	35
176	Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers. World Journal of Gastroenterology, 2014, 20, 9229-36.	1.4	51
177	Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. Hepatology International, 2013, 7, 144-152.	1.9	8
178	Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient. Clinical Journal of Gastroenterology, 2013, 6, 160-163.	0.4	3
179	Treatment of hepatitis C virus infection in the future. Clinical and Translational Medicine, 2013, 2, 9.	1.7	27
180	Different effects of three interferons L on Toll-like receptor-related gene expression in HepG2 cells. Cytokine, 2013, 64, 577-583.	1.4	12

#	Article	IF	Citations
181	Lipopolysaccharide blocks induction of unfolded protein response in human hepatoma cell lines. Immunology Letters, 2013, 152, 8-15.	1.1	13
182	Hepatitis C Virus and Hepatocellular Carcinoma. Biology, 2013, 2, 304-316.	1.3	22
183	Acute Liver Failure Occurring during the First Trimester of Pregnancy Successfully Treated with Living Donor Liver Transplantation. Case Reports in Transplantation, 2013, 2013, 1-4.	0.1	1
184	Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy. International Journal of Medical Sciences, 2013, 10, 43-49.	1.1	4
185	Efficacy of Lamivudine or Entecavir against Virological Rebound after Achieving HBV DNA Negativity in Chronic Hepatitis B Patients. International Journal of Medical Sciences, 2013, 10, 647-652.	1.1	10
186	Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment. International Journal of Medical Sciences, 2013, 10, 1015-1021.	1.1	9
187	Platelet count and sustained virological response in hepatitis C treatment. World Journal of Hepatology, 2013, 5, 182.	0.8	11
188	No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV. PLoS ONE, 2013, 8, e81312.	1.1	30
189	Prevalence of Hepatitis C Virus Subgenotypes 1a and 1b in Japanese Patients: Ultra-Deep Sequencing Analysis of HCV NS5B Genotype-Specific Region. PLoS ONE, 2013, 8, e73615.	1.1	29
190	Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World Journal of Gastroenterology, 2013, 19, 8940.	1.4	33
191	Androgen Receptor and Hepatocellular Carcinoma. , 2013, 01, .		1
192	IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. World Journal of Hepatology, 2013, 5, 635.	0.8	2
193	Role of IL28B genotype in older hepatitis C virus-infected patients. World Journal of Immunology, 2013, 3, 54.	0.5	3
194	Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients. Chinese Medical Journal, 2013, 126, 4568-74.	0.9	6
195	Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin. Viruses, 2012, 4, 1264-1278.	1.5	23
196	Hepatitis B Virus e Antigen Physically Associates With Receptor-Interacting Serine/Threonine Protein Kinase 2 and Regulates IL-6 Gene Expression. Journal of Infectious Diseases, 2012, 206, 415-420.	1.9	32
197	Interleukin-29 Suppresses Hepatitis A and C Viral Internal Ribosomal Entry Site-Mediated Translation. Viral Immunology, 2012, 25, 379-386.	0.6	18
198	Acute Liver Failure in an Antimitochondrial Antibody-Positive 63-Year-Old Man. Case Reports in Gastroenterology, 2012, 6, 394-399.	0.3	2

#	Article	IF	Citations
199	APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatology International, 2012, 6, 409-435.	1.9	152
200	Possible widespread presence of hepatitis A virus subgenotype IIIA in Japan: Recent trend of hepatitis A causing acute liver failure. Hepatology Research, 2012, 42, 248-253.	1.8	20
201	Hepatitis A outbreak associated with a revolving sushi bar in Chiba, Japan: Application of molecular epidemiology. Hepatology Research, 2012, 42, 828-834.	1.8	27
202	Hepatitis A, B, C and E virus markers in Chinese residing in Tokyo, Japan. Hepatology Research, 2012, 42, 974-981.	1.8	15
203	Efficacy of Lamivudine or Entecavir on Acute Exacerbation of Chronic Hepatitis B. International Journal of Medical Sciences, 2012, 9, 27-32.	1.1	9
204	Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients. PLoS ONE, 2011, 6, e28617.	1.1	24
205	Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scandinavian Journal of Gastroenterology, 2011, 46, 955-961.	0.6	35
206	Response to Peginterferon-alfa 2b and Ribavirin in Japanese Patients with Chronic Hepatitis C Genotype 2. Digestive Diseases and Sciences, 2011, 56, 3335-3342.	1.1	25
207	Hepatitis C Virus Nonstructural 5A Protein Inhibits Lipopolysaccharide-Mediated Apoptosis of Hepatocytes by Decreasing Expression of Toll-Like Receptor 4. Journal of Infectious Diseases, 2011, 204, 793-801.	1.9	43
208	Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients. Oncology, 2011, 80, 366-372.	0.9	15
209	Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication. Scandinavian Journal of Gastroenterology, 2011, 46, 1111-1117.	0.6	23
210	New antiviral therapies for chronic hepatitis C. Hepatology International, 2010, 4, 548-561.	1.9	99
211	Analysis of 5′ Nontranslated Region of Hepatitis A Viral RNA Genotype I from South Korea: Comparison with Disease Severities. PLoS ONE, 2010, 5, e15139.	1.1	19
212	Hepatitis C Virus Infection Impairs IRF-7 Translocation and Alpha Interferon Synthesis in Immortalized Human Hepatocytes. Journal of Virology, 2010, 84, 10991-10998.	1.5	44
213	Hepatitis B Virus e Antigen Downregulates Cytokine Production in Human Hepatoma Cell Lines. Viral Immunology, 2010, 23, 467-476.	0.6	32
214	Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha. Virology Journal, 2010, 7, 212.	1.4	28
215	Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. Journal of Hepatology, 2010, 52, 72-78.	1.8	53
216	Internal ribosomal entryâ€site activities of clinical isolateâ€derived hepatitis A virus and inhibitory effects of amantadine. Hepatology Research, 2010, 40, 415-423.	1.8	15

#	Article	IF	Citations
217	Inhibition of Intrahepatic Gamma Interferon Production by Hepatitis C Virus Nonstructural Protein 5A in Transgenic Mice. Journal of Virology, 2009, 83, 8463-8469.	1.5	35
218	MBP-1 Inhibits Breast Cancer Growth and Metastasis in Immunocompetent Mice. Cancer Research, 2009, 69, 9354-9359.	0.4	13
219	Opportunistic infection in the patients with acute liver failure: a report of three cases with one fatality. Clinical Journal of Gastroenterology, 2009, 2, 420-424.	0.4	4
220	Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scandinavian Journal of Gastroenterology, 2009, 44, 872-877.	0.6	15
221	Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virusâ€infected and hepatitis C virusâ€cleared patients. Liver International, 2008, 28, 355-362.	1.9	90
222	Hepatitis C Virus Core Protein Augments Androgen Receptor-Mediated Signaling. Journal of Virology, 2008, 82, 11066-11072.	1.5	76
223	Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells. Journal of Virology, 2007, 81, 3933-3941.	1.5	64
224	Small Interfering RNA Targeted to Hepatitis C Virus 5′ NontranslatedRegion Exerts Potent Antiviral Effect. Journal of Virology, 2007, 81, 669-676.	1.5	80
225	Hepatitis C Virus Infection Induces the Beta Interferon Signaling Pathway in Immortalized Human Hepatocytes. Journal of Virology, 2007, 81, 12375-12381.	1.5	46
226	Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis in relation to HBeAg and anti-HBe. Journal of Medical Virology, 2007, 79, 683-693.	2.5	6
227	Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Science, 2007, 98, 1921-1929.	1.7	14
228	Inhibition of subgenomic hepatitis C virus RNA replication in HeLa cells. Hepato-Gastroenterology, 2007, 54, 32-5.	0.5	1
229	Body mass index in Japanese patients with autoimmune liver disease: overweight patients with primary biliary cirrhosis tend to be asymptomatic. Hepato-Gastroenterology, 2007, 54, 1758-60.	0.5	3
230	Hepatitis A protein VP1-2A reduced cell viability in Huh-7 cells with hepatitis C virus subgenomic RNA replication. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 625-626.	1.4	3
231	Occurrence of Autoimmune Hepatitis During the Course of Primary Biliary Cirrhosis: Report of Two Cases. Digestive Diseases and Sciences, 2006, 51, 45-46.	1.1	9
232	Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes. Journal of Virology, 2006, 80, 4633-4639.	1.5	84
233	Silencing of Hepatitis A Virus Infection by Small Interfering RNAs. Journal of Virology, 2006, 80, 5599-5610.	1.5	55
234	5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. Oncology Reports, 2005, 14, 975.	1.2	12

#	Article	IF	Citations
235	Prolonged hepatitis caused by cytomegalovirus and non-alcoholic steatohepatitis in 16-year-old obese boy. European Journal of Pediatrics, 2005, 164, 212-215.	1.3	4
236	Enhanced Sensitivity of Human Hepatoma Cells to 5-Fluorouracil by Small Interfering RNA Targeting Bcl-2. DNA and Cell Biology, 2005, 24, 805-809.	0.9	19
237	Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site. Biochemical and Biophysical Research Communications, 2005, 330, 1217-1223.	1.0	32
238	Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochemical and Biophysical Research Communications, 2005, 331, 621-629.	1.0	32
239	Prolonged acute hepatitis A mimicking autoimmune hepatitis. World Journal of Gastroenterology, 2005, $11,3791$.	1.4	13
240	Prevalence of obesity in patients with acute hepatitis; is severe obesity a risk factor for fulminant hepatitis in Japan?. Hepato-Gastroenterology, 2005, 52, 180-2.	0.5	2
241	Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepato-Gastroenterology, 2005, 52, 1233-5.	0.5	10
242	5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. Oncology Reports, 2005, 14, 975-9.	1.2	26
243	Interference of hepatitis A virus replication by small interfering RNAs. Biochemical and Biophysical Research Communications, 2004, 318, 341-345.	1.0	36
244	Severe hypercholesterolemia associated with primary biliary cirrhosis in a 44-year-old Japanese woman. World Journal of Gastroenterology, 2004, 10, 2607.	1.4	5
245	Acute hepatitis C virus infection, 1986-2001: a rare cause of fulminant hepatitis in Chiba, Japan. Hepato-Gastroenterology, 2004, 51, 556-8.	0.5	8
246	Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology, 2003, 37, 19-26.	3.6	362
247	SEVERE HEPATOTOXICITY ASSOCIATED WITH CHINESE DIET PRODUCT 'ONSHIDOU-GENBI-KOUNOU'. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 354-355.	1.4	20
248	N-Nitroso-Fenfluramine Hepatotoxicity Resembling Chronic Hepatitis. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 999-1000.	1.4	28
249	Bezafibrate treatment: a new medical approach for PBC patients?. Journal of Gastroenterology, 2003, 38, 573-578.	2.3	121
250	Fulminant hepatic failure associated with benzbromarone treatment: A case report. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 625-626.	1.4	64
251	Fulminant hepatic failure associated with triazolam. Digestive Diseases and Sciences, 2002, 47, 1111-1114.	1.1	20
252	Sequenceâ€motif analysis of 5′â€untranslated region of GB virusâ€C in Japanese patients. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 1048-1053.	1.4	1

Tatsuo Kanda

#	Article	IF	CITATIONS
253	The role of TT virus infection in acute viral hepatitis. Hepatology, 1999, 29, 1905-1908.	3.6	66